Senators ask FDA for biosimliar naming rules

Share this article:

Lawmakers are prodding the FDA to come to a decision about biosimilar naming. The Wall Street Journal reports that senators have asked the regulator to issue rules soon, particularly because Novartis's Sandoz subsidiary put a lookalike biologic up for review last month, and that drug will need a name.

Branded biologics makers want their drugs to have distinct international proprietary names—the ones that typically appear in parenthesis after a brand name, as in Rituxan (rituximab)—from those of copies. They have defended this position in part by saying a biologic made by another drugmaker would not be a duplicate of the original drug, so an almost-twin should not share the same name. The Journal notes that manufacturers of branded drugs have also defended this position by saying it would be easier to track adverse events if every biologic had its own name.

Opponents say that having distinct names for each biosimilar would make it harder to see a substitution as like-for-like.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.